Update on adjuvant chemotherapy for early breast cancer

ONCOLOGY

Volumn 14, Issue 9, 2000, Pages 1267-1280

  Mccarthy, Nicole J ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS;

EID: 0034278086     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998.
2. Pritchard KI: Endocrine therapy for breast cancer. Oncology 14:483-492, 2000.
3. Hutchins L, Green S, Ravdin P, et al: CMF vs CAP with and without tamoxifen in high-risk nodenegative breast cancer patients and a natural history follow-up. Study in low-risk node-negative patients: First results of Intergroup Trial INT 0102 (abstract 2). Proc Am Soc Clin Oncol 17:1a, 1998.
4. Levine MM, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women .with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998.